Results 61 to 70 of about 3,395 (155)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions

MedComm, Volume 6, Issue 11, November 2025.
Summary of PCSK9 inhibitor mechanisms. PCSK9 inhibitors (PCSK9‐i) primarily lower LDL‐cholesterol (LDL‐C) by blocking PCSK9‐mediated degradation of hepatic LDL receptors (LDLR), enhancing LDL clearance. Beyond LDLR‐dependent effects, PCSK9‐i exert multiple benefits via LDLR‐independent pathways.
Jia Kuang, Lei Hao, Meibiao Zhang, Zhao Yang   +3 more
wiley   +1 more source

Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES

American Journal of Preventive Cardiology
Background: Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS.
Gregory P. Geba, Ruifeng Chen, Kasturi Talapatra, Taylor Brackin, Kusha A. Mohammadi, Robert Pordy, Garen Manvelian, David J. Maron, Gregory G. Schwartz, Michael Szarek, Ph. Gabriel Steg, Sergio Fazio   +11 more
doaj   +1 more source

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

JACC: Basic to Translational Science, 2016
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and
Elise F. Villard, PhD, Aurélie Thedrez, PhD, Jorg Blankenstein, PhD, Mikaël Croyal, BSc, Thi-Thu-Trang Tran, PhD, Bruno Poirier, PhD, Jean-Christophe Le Bail, PhD, Stéphane Illiano, PhD, Estelle Nobécourt, MD, PhD, Michel Krempf, MD, PhD, Dirk J. Blom, MD, PhD, A. David Marais, MD, Philip Janiak, PhD, Anthony J. Muslin, MD, PhD, Etienne Guillot, PhD, Gilles Lambert, PhD   +15 more
doaj   +1 more source

RE: Praluent (Alirocumab)-Induced Renal Injury [PDF]

Journal of Pharmacy Practice, 2017
Author(s): Rosenson, Robert S; Larrey, Dominique; Waters, David D; Olsson, Anders G; Members of the Phase 3 Data Monitoring Committee for ...
Rosenson, Robert, Larrey, Dominique, Waters, David, Olsson, Anders   +3 more
openaire   +5 more sources

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1835-1847, November 2025.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

Miscellanea. Folyóirat-referátumok. Beszámoló [PDF]

, 2016
Hypertonia A déli sziesztának (alvás-szunyókálás) és időtartamának hatása a vérnyomás alakulására magas vérnyomásban szenvedő betegek körében (Asociation of mid-day naps occurence and duration with blood pressure levels in hypertensive ...
Apor, Péter, Benkő, Ria, Blázovics, Anna, Fischer, Tamás, Hankis, János, Jakobovits, Antal   +5 more
core   +1 more source

Statins Regulate Stem Cell Growth Factor‐β to Balance Osteogenesis and Adipogenesis in Mesenchymal Stem Cells, Endowing Anti‐Osteonecrosis Effects

Journal of Cellular and Molecular Medicine, Volume 29, Issue 22, November 2025.
ABSTRACT Dyslipidaemia has been implicated in osteonecrosis through some clinical studies. However, a direct causal relationship between hyperlipidaemia and osteonecrosis remains unconfirmed, and whether lipid‐lowering agents could be used to treat osteonecrosis remains unclear.
Fangzhou Fan, Yu Chen, Weiyan Peng, Wenlong Yan, Hao Tan, Chengxuan Zhang, Siyu Tan, Qian Xiao, Yuan Gao, Jian Zhang, Lei Liu, Chengjie Lian   +11 more
wiley   +1 more source

Experiencia del paciente en tratamiento con inhibidores de pcsk9 con el modelo de atención farmacéutica cmo [PDF]

, 2019
La Atención Farmacéutica clásica se basa en la identificación, resolución y prevención de los PRM, excluyendo como factor principal los problemas asociados al paciente.
Garcés Troncoso, Vanessa
core  

Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms

Advanced Science, Volume 12, Issue 37, October 6, 2025.
Cardiovascular disease (CVD) and cancer are leading causes of death worldwide, with overlapping risk factors and pathophysiological mechanisms. This review explores shared pathways, including metabolic dysregulation, chronic inflammation, and gut microbiome alterations, highlighting dual‐benefit strategies such as lifestyle modifications and repurposed
Shihan Xiang, Yujie Shan, Shihong Xu, Jing Wang, Meng Luo, Jiaojiao Zhou, Qishan Chen   +6 more
wiley   +1 more source

Cholesterol‐lowering drug targets reduce risk of dementia: Mendelian randomization and meta‐analyses of 1 million individuals

Alzheimer's &Dementia, Volume 21, Issue 10, October 2025.
Abstract INTRODUCTION We tested whether genetically proxied non‐high‐density lipoprotein cholesterol (non‐HDL‐C)–lowering drug targets reduce risk of all‐cause dementia. METHODS We included 1,091,775 individuals from three prospective general population cohorts with individual‐level data and two consortia with summary‐level data.
Liv Tybjærg Nordestgaard, Aimee Hanson, Eleanor Sanderson, Emma Anderson, Venexia Walker, Anne Tybjærg‐Hansen, George Davey Smith, Børge G. Nordestgaard   +7 more
wiley   +1 more source